Rxsight Inc. is a cutting-edge healthcare technology company dedicated to transforming vision correction through advanced diagnostic and surgical solutions in refractive eye surgery. By integrating proprietary software with precision laser systems, Rxsight aims to significantly improve patient outcomes and enhance the quality of life for those seeking vision correction. The company boasts a robust intellectual property portfolio and strategic collaborations that position it favorably within the growing ophthalmic market. Committed to innovation and operational excellence, Rxsight is poised to drive substantial advancements in eye care, reflecting its potential for sustained growth and impact in the sector.
| Revenue (TTM) | $127.58M |
| Gross Profit (TTM) | $98.88M |
| EBITDA | $-51.58M |
| Operating Margin | -40.80% |
| Return on Equity | -17.30% |
| Return on Assets | -10.40% |
| Revenue/Share (TTM) | $3.09 |
| Book Value | $6.33 |
| Price-to-Book | 0.77 |
| Price-to-Sales (TTM) | 1.52 |
| EV/Revenue | 0.0308 |
| EV/EBITDA | -7.70 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.30% |
| Shares Outstanding | $41.59M |
| Float | $33.71M |
| % Insiders | 6.57% |
| % Institutions | 104.44% |
Volatility is currently contracting
K2 Vision has performed 5,000+ Light Adjustable Lens procedures and is recognized by RxSight as the highest-volume LAL practice in the world. Learn more.
ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. ET in Boston, Massachusetts. A live and archived webcast of the presentation will be available on the Company's investor relations website at https://investors.rxsight.com/.
RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript
RxSight NASDAQ: RXST reported second-quarter revenue of $33.7 million, including $6.5 million recognized under its strategic collaboration with Alcon, while management withdrew its full-year 2026 financial guidance as new Chief Executive Officer Aziz Mottiwala conducts a broader assessment of the business.
ALISO VIEJO, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, and provided an update on its 2026 financial outlook.
RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALISO VIEJO, Calif., July 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on July 24, 2026, RxSight granted inducement stock options to purchase a total of 571,286 shares of RxSight's common stock and inducement restricted stock units (RSUs) covering a total of 2,312,138 shares of RxSight's common stock to Aziz Mottiwala, RxSight's new President and Chief Executive Officer in connection with his commencement of employment with RxSight.
RxSight (RXST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ALISO VIEJO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced a planned leadership transition effective July 20, 2026, with Aziz Mottiwala appointed President and Chief Executive Officer, succeeding Ron Kurtz, M.D., who will continue to serve as Chief Medical Officer.
ALC is developing adjustable presbyopia-correcting lenses that pair advanced optics with post-surgery light adjustment.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RXST and any ticker you trade — then tracks every position and per-strategy win rate.
